PI Pharma Insight

BNF presentation directory

Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.

Reset

Active filters

  • Chemical substance: Methylprednisolone acetate
Presentation Product Chemical substance Chapter Items dispensed
Depo-Medrone 40mg/1ml suspension for injection vials
1001022K0BBAAAA
Depo-Medrone Methylprednisolone acetate Musculoskeletal and Joint Diseases 54,412
Depo-Medrone with Lidocaine inj 1ml vials
1001022K0BBAGAG
Depo-Medrone Methylprednisolone acetate Musculoskeletal and Joint Diseases 34,662
Depo-Medrone with Lidocaine inj 2ml vials
1001022K0BBAFAF
Depo-Medrone Methylprednisolone acetate Musculoskeletal and Joint Diseases 19,998
Methylprednisolone acetate 40mg/1ml inj vials
1001022K0AAAAAA
Methylprednisolone acetate Methylprednisolone acetate Musculoskeletal and Joint Diseases 13,902
Depo-Medrone 80mg/2ml suspension for injection vials
1001022K0BBABAB
Depo-Medrone Methylprednisolone acetate Musculoskeletal and Joint Diseases 13,288
Methylprednisolone 40mg / Lidocaine 10mg/1ml (1%) inj vials
1001022K0AAAGAG
Methylprednisolone acetate Methylprednisolone acetate Musculoskeletal and Joint Diseases 8,730
Methylprednisolone 80mg / Lidocaine 20mg/2ml (1%) inj vials
1001022K0AAAFAF
Methylprednisolone acetate Methylprednisolone acetate Musculoskeletal and Joint Diseases 5,162
Methylprednisolone acetate 80mg/2ml inj vials
1001022K0AAABAB
Methylprednisolone acetate Methylprednisolone acetate Musculoskeletal and Joint Diseases 2,976
Depo-Medrone 120mg/3ml suspension for injection vials
1001022K0BBAEAE
Depo-Medrone Methylprednisolone acetate Musculoskeletal and Joint Diseases 881
Methylprednisolone acetate 120mg/3ml inj vials
1001022K0AAAEAE
Methylprednisolone acetate Methylprednisolone acetate Musculoskeletal and Joint Diseases 527

Why monitor BNF codes?

Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.

Track cost pressure

Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.

Understand demand drivers

Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.